MTA2 (metastasis-associated protein 2) functions as a transcriptional coregulator and core component of the nucleosome remodeling and histone deacetylation (NuRD) complex 12. The NuRD complex participates in chr11 remodeling by coupling ATP-dependent nucleosome remodeling with histone deacetylase activity 3. MTA2 serves as a central hub linking nuclear transcriptional regulation with cytoskeletal organization 4. Mechanism: MTA2 operates within the NuRD complex as part of its initial assembly with histone chaperone RBBP7 3. MTA2 knockdown induces mesendoderm specification in human embryonic stem cells through a pathway involving DYRK4 inhibition 5. The protein prevents genome instability by protecting against transcription-replication conflicts and R-loop-mediated DNA damage 6. Disease Relevance: MTA2 is highly expressed in most cancers and associates with poor prognosis across 33 cancer types 7. High MTA2 expression correlates with aggressive tumor behavior in breast and ovarian cancers, with expression linked to tumor stage, histopathological grade, and metastatic potential 89. MTA2 mutations show positive selection in clonal hematopoiesis, correlating with heightened infection, mortality, and hematological malignancy risk 10. Clinical Significance: MTA2 serves as a prognostic marker for various malignancies. MK-886, a candidate MTA2-targeting drug, inhibits hepatocellular carcinoma cell proliferation dose-dependently 7.